Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia Disorders Clear all
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Schizophrenia

NCT01810783
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCT05227703
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine 15 mg, Emraclidine 30 mg, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

My Experiences: Leveraging Digital Technologies to Better Understand Mental Health

NCT05753605
View directory record Official record
Conditions
Mental Health Symptoms, Wearables
Interventions
Not listed
Lead sponsor
4YouandMe
Other
Eligibility
18 Years and older
Enrollment
302 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
Interventions
LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Garden Grove, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole in Patients With Acute Schizophrenia

NCT01810380
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Brexpiprazole, Quetiapine extended release
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SPARK Healthy Sleep

NCT07119268
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Sleep Disturbance
Interventions
SPARK Healthy Sleep
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCT00235352
View directory record Official record
Conditions
Schizophrenia
Interventions
CX516 (Ampakine)
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Risperidone Implants

NCT02773576
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

NCT00125138
View directory record Official record
Conditions
Parkinson's Disease, Psychotic Disorders
Interventions
Melperone HCl, Placebo
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Bradenton, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

NCT02034474
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Risk State for Bipolar Disorder in Adolescents

NCT01383915
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 18 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Results available

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

NCT03892889
View directory record Official record
Conditions
Schizophrenia
Interventions
Abilify MyCite®
Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
68
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

NCT03437668
View directory record Official record
Conditions
Schizophrenia
Interventions
WSE, Placebo Oral Tablet
Drug
Lead sponsor
Chengappa, K.N. Roy, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis

NCT01216891
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychosis
Interventions
Multi-element, team-oriented treatment
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
15 Years to 35 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Rehabilitative Training for Older People With Schizophrenia

NCT00071591
View directory record Official record
Conditions
Schizophrenia
Interventions
Functional Adaptation Skills Training (FAST)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2013 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia

NCT07190352
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder), Nicotine Use
Interventions
iTBS to the DMN, cTBS to the DMN, Sham rTMS
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Digoxin Drug-Drug Interaction With Lurasidone HCl

NCT01082289
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Not applicable Interventional Results available

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

NCT03648268
View directory record Official record
Conditions
Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults

NCT01266174
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
Eltoprazine, Placebo
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Catonsville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714713
View directory record Official record
Conditions
Schizophrenia, Impaired Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
830 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
69
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 17, 2026, 4:09 AM EDT
Enrolling by invitation Not applicable Interventional

Mindfulness-Based Therapy for Serious Mental Illness

NCT06880796
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Major Depressive Disorder, Bipolar Disorder
Interventions
Mindfulness-based therapy, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 17, 2026, 4:09 AM EDT